MLM
SRPT icon

Mount Lucas Management’s Sarepta Therapeutics SRPT Stock Holding History

Mount Lucas Management’s Portfolio SRPT Stock Details SRPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-1,810
Closed -$234K – 184
2024
Q1 		$234K Sell
1,810
-162
-8% -$19.8K 0.06% 139
2023
Q4 		$190K Sell
1,972
-2
-0.1% -$192 0.05% 139
2023
Q3 		$239K Sell
1,974
-254
-11% -$28.7K 0.08% 119
2023
Q2 		$255K Buy
+2,228
New +$287K 0.09% 135

Other funds holding SRPT

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Mount Lucas Management's SRPT Position: Q2 2024 in Review

Mount Lucas Management sold out of Sarepta Therapeutics (SRPT) in Q2 2024, closing a stake of 1,810 shares — an estimated $234K sold.

Mount Lucas Management first reported a position in SRPT in Q2 2023 and held it in 4 quarters. The position peaked at $255K in Q2 2023. 483 funds tracked by Wall St. Rank hold SRPT as of Q2 2024.

  • Mount Lucas Management reported no remaining Sarepta Therapeutics position as of Q2 2024 after selling out during the quarter.
  • Mount Lucas Management sold 1,810 Sarepta Therapeutics shares in Q2 2024, an estimated $234K.
  • Mount Lucas Management first reported a position in Sarepta Therapeutics in Q2 2023 and held it in 4 quarters.
  • Mount Lucas Management's Sarepta Therapeutics position peaked at $255K in Q2 2023.
  • 483 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q2 2024.

Based on Mount Lucas Management's 13F filing for Q2 2024, filed 6 Aug 2024.